来瑞特韦

来瑞特韦
臨床資料
商品名（英语：Drug nomenclature）	乐睿灵
其他名稱	RAY1216
法律規範狀態
法律規範	中：处方药 ;
识别信息
	IUPAC命名法 (3S,3aS,6aR)-2-[(2S)-2-cyclohexyl-2-[(2,2,2-trifluoroacetyl)amino]acetyl]-N-[(2S)-4-(cyclopentylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; ;
CAS号	2923310-64-7
PubChem CID	167713195;
ChemSpider	128922060;
ChEMBL	ChEMBL5422898;
化学信息
化学式	C31H44F3N5O6
摩尔质量	639.72 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C1CCC(CC1)[C@@H](C(=O)N2C[C@@H]3CCC[C@@H]3[C@H]2C(=O)N[C@@H](C[C@@H]4CCNC4=O)C(=O)C(=O)NC5CCCC5)NC(=O)C(F)(F)F;
	InChI InChI=1S/C31H44F3N5O6/c32-31(33,34)30(45)38-23(17-7-2-1-3-8-17)29(44)39-16-19-9-6-12-21(19)24(39)27(42)37-22(15-18-13-14-35-26(18)41)25(40)28(43)36-20-10-4-5-11-20/h17-24H,1-16H2,(H,35,41)(H,36,43)(H,37,42)(H,38,45)/t18-,19-,21-,22-,23-,24-/m0/s1; Key:ICGMMLTUQDVAST-HEZDJTGRSA-N;

来瑞特韦（英語：Leritrelvir，研发代号：RAY1216），商品名乐睿灵，是一种抗病毒药物，具有3C样蛋白酶抑制剂作用。该药物由中国大陆研发并获批^[1]用于治疗新冠感染（COVID-19）^[2]^[3]^[4]^[5]。

参考文献

^ Zheng L, Wang W, Sun Q. Targeted drug approvals in 2023: Breakthroughs by the FDA and NMPA. Signal Transduction and Targeted Therapy. 2024, 9 (1): 46. PMC 10879080 . PMID 38378623. doi:10.1038/s41392-024-01770-y.
^ Janin YL. On the origins of SARS-CoV-2 main protease inhibitors. RSC Medicinal Chemistry. 2024-01, 15 (1): 81–118. PMC 10809347 . PMID 38283212. doi:10.1039/d3md00493g.
^ Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, Huang Y, Dai M, Qin B, Ong CP, Chu AW, Chan WM, Ip JD, Wen L, Tsang JO, Wang TY, Xie Y, Qin Z, Cao J, Ye ZW, Chu H, To KK, Ge XY, Ni T, Jin DY, Cui S, Yuen KY, Yuan S. Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. Acta Pharmaceutica Sinica. B. 2024-09, 14 (9): 4028–4044. PMC 11413674 . PMID 39309487. doi:10.1016/j.apsb.2024.05.026.
^ Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, Wang W, Bi Y, Ning G, Xu Y, Zhao R. Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116). Frontiers of Medicine. 2023-12, 17 (6): 1068–1079. PMID 38165534. doi:10.1007/s11684-023-1037-3.
^ Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G. Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis. International Journal of Antimicrobial Agents. 2024-03, 63 (3): 107096. PMID 38244811. doi:10.1016/j.ijantimicag.2024.107096 .